<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Labcorp Completes Acquisition of Select Assets of BioReference Health&#x27;s Innovative Oncology and Related Clinical Testing Services Businesses — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Labcorp Completes Acquisition of Select Assets of BioReference Health&#x27;s Innovative Oncology and Related Clinical Testing Services Businesses</h2>
    <div class="badge">2025-09-15T12:30:00+00:00</div>
    <ul>
      <li>The company&#x27;s nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 mill</li>
<li>We intend to utilize a portion of the proceeds to fund our recently expanded share repurchase authorization.&quot; BioReference Health&#x27;s continuing operations include its core clinical testing operations in the New York and N</li>
<li>15, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc.</li>
<li>The purchase price for the transaction is up to $225 million, including $192.5 million that was paid at closing and up to $32.5 million in an earnout based on performance.</li>
<li>and MIAMI, Sept.</li>
<li>Piper Sandler &amp; Co.</li>
<li>Learn more about us at www.labcorp.com</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Labcorp Completes Acquisition of Select Assets of BioReference Health&amp;#x27;s Innovative Oncology and Related Clinical Testing Services Businesses\n• The company&#x27;s nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 mill\n• We intend to utilize a portion of the proceeds to fund our recently expanded share repurchase authorization.&quot; BioReference Health&#x27;s continuing operations include its core clinical testing operations in the New York and N\n• 15, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc.\n• The purchase price for the transaction is up to $225 million, including $192.5 million that was paid at closing and up to $32.5 million in an earnout based on performance.\n• and MIAMI, Sept.\n• Piper Sandler &amp; Co.\n• Learn more about us at www.labcorp.com" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/labcorp-completes-acquisition-select-assets-123000533.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>